IS M8969 safety and PK/PD in healthy and at-risk adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, Phase 1, randomized, double-blind, placebo-controlled study with sequential dosing. It evaluates single and multiple ascending oral doses of ISM8969 in healthy adults (including older adults) and obese adults at cardiovascular risk. The study looks at safety, tolerability, pharmacokinetics, and pharmacodynamics. Participants receive ISM8969 or placebo in a controlled, dose-escalation framework to identify initial safety signals and PK/PD profiles. Lead sponsor is InSilico Medicine Hong Kong Limited, with Nucleus Network Pty Ltd in Melbourne as the site.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Participants must meet all the following criteria to be included in the study:

Inclusion criteria 1\~4 are only for the healthy participants in the SAD and MAD study:

1. Male or female participants, including adult participants (≥18 and \<65 years of age) for the SAD cohorts 1-6 and MAD cohorts 1-3, and elderly participants (≥65 and ≤80 years of age) for MAD cohort 4.
2. Body mass index (BMI) \>18.5 and \<30.0 kg/m2 and body weight ≥50.0 kg for males and ≥45.0 kg for females.
3. Non-smokers (no use of tobacco or nicotine products within 1 month prior to screening).
4. Healthy as defined the current protocol.

   Inclusion criteria 5\~9 are only for the obese participants at risk of cardiovascular disease in MAD study):
5. Male or female, ≥18 and ≤65 years of age.
6. 30.0 kg/m2 ≤ BMI \< 42.0 kg/m2.
7. No change in body weight or self-reported change of less than 5.0% within 3 months before screening.
8. Presence of 1 or more risk factors for cardiovascular disease such as hypertension, hyperlipidemia. If present, must be controlled with stable medication dose/therapy (defined as a stable medication dose/therapy for 3 months or longer).
9. hsCRP ≥3 mg/L.

Exclusion Criteria:

Participants for whom any of the following applies will be excluded from the study:

1. Columbia suicide severity rating scale (C-SSRS) score above Type 1 ideation.
2. Positive serology test results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antigen and antibody, treponema pallidum antibody or QuantiFERON®-TB test at screening.
3. Positive pregnancy test or lactating female participant.
4. History of any central nervous system (CNS) disorder or history of seizure of any cause.
5. Clinically significant 12-lead ECG, physical examination, vital signs or laboratory abnormalities at screening, including but not limited to defined in the protocol.
6. History of significant cardiovascular or cerebrovascular disease within 6 months before screening, including but not limited to defined in the protocol.
7. History of an active or untreated malignancy or are in remission from a clinically significant malignancy (other than basal- or squamous-cell skin cancer, or in situ carcinomas of the cervix) for less than 5 years; or there is a potential malignancy during screening.
8. Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days (or 5 half-lives, whichever is longer) prior to the first dosing, administration of a biological product in the context of a clinical research study within 90 days (or 5 half-lives, whichever is longer) prior to the first dosing, or concomitant participation in an investigational study involving no drug or device administration.
9. Presence of contraindication to lumbar puncture or lumbar catheter as judged by Investigator.

Where it's running

• Nucleus Network Pty Ltd.
  Melbourne, Victoria, Australia Recruiting

Study contacts

• Study coordinator: Johnny Ju
• Email: Insilico-Clinicaltrial@insilico.ai
• Phone: +86 021-50831718

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Bioequivalence comparison between YHP2508B and YHR2602 in healthy adults

  This study tests whether YHP2508B and YHR2602 deliver similar amounts of the drug in healthy adults after a single dose.

  Recruiting Phase 1 Yuhan Corporation · Gimpo-si · NCT07912840

• Bioequivalence test of two drugs in healthy adults

  This study tests whether YHP2508A and YHR2601 are bioequivalent in healthy volunteers.

  Recruiting at 2 sites Phase 1 Yuhan Corporation · Seoul and 1 other locations · NCT07912827

• Reactive Balance Training with Augmented Reality for Older Adults

  This study tests whether reactive balance training using augmented reality helps older adults who are at risk of falling, compared with regular treadmill walking.

  Recruiting The Hong Kong Polytechnic University · Hong Kong · NCT07860619

• How the body responds to exercise with low oxygen in healthy adults

  Researchers test how healthy men and women respond to different exercise types while breathing air with varying oxygen levels.

  Recruiting University Hospital, Grenoble · La Tronche · NCT07671638

• Ear-based vagus nerve stimulation to improve reaction time

  Researchers will try a short, noninvasive electrical stimulation of the vagus nerve at the ear to see if it shortens reaction time in healthy adults.

  Recruiting Youngstown State University · Youngstown, Ohio · NCT07528742

• Single ascending-dose safety and response test of SYH2070 injection in healthy adults

  This test gives a single subcutaneous dose of SYH2070 to healthy adults with mildly high triglycerides to see whether it is safe, how the body handles it, and whether it causes early biological effects compared with placebo.

  Recruiting Phase 1 CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Shijiazhuang, Hebei · NCT07241923

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.